AGMB-129 is under clinical development by AgomAb Therapeutics and currently in Phase I for Colon Cancer. According to GlobalData, Phase I drugs for Colon Cancer have a 56% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how AGMB-129’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AGMB-129 overview

AGMB-129 is under development for the treatment of colon cancer and crohn's disease. It is administered orally as a capsule. The drug candidate acts by targeting ALK5.

AgomAb Therapeutics overview

AgomAb Therapeutics (AgomAb) is a biotech company that develop growth factor mimetic agonistic monoclonal antibodies to regenerate damaged tissues and has produced a comprehensive preclinical package illustrating different applications in the fields of fibrotic, inflammatory, autoimmune and degenerative diseases. AgomAb provide novel treatment to restore organ functions. The company combining new scientific insights with robust drug development and build a broad clinical pipeline of differentiated programs with disease modifying potential in severe organ failure and fibrotic diseases. The company operates its research laboratory in Italy and Spain. AgomAb is headquartered in Ghent, Belgium.

For a complete picture of AGMB-129’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.